Trans-Atlantic Conference Programming

  • Panels and Luncheon Thursday June 23rd

    8 AM. Regulatory and Reimbursement Issues. Understanding the business of getting approval in Europe. Is this a superior Strategy than to seek approval in the United States? What are the distinctions of both?

    Recent studies have indicated that the time to gain approval is dramatically different from a CE Mark for Europe than a 510K in the United States. Increasingly, companies are launching in Europe while waiting for approval in the United States. This session will explore the merits of this strategy in terms of creating capital efficiency. It will consider other strategic planning considerations in the process of getting approval and reimbursement. The morning session will explore the implications of this for emerging companies and investors and will focus on a case study of how to get approval. We will look at a case study and hear from those with experience to provide guidance on how to do this in a capital efficient manner. The panel will consider how this is done in Europe as well as in the United States.

    Rosina Robinson, RN, M.Ed., RAC, Principal Consultant, Regulatory Services
    Corinne Lebourgeois, Managing Director, MedC. Partners
    Richard Naples, SVP, Corporate Regulatory Affairs and Compliance, BD
    Full Bios

    12:30 PM. Luncheon. Speaker:

    Paul H. Keckley, PhD, Executive Director, Deloitte Center for Health Solutions, Washington, D.C.

    Paul H. Keckley, Ph.D., is Executive Director for the Deloitte Center for Health Solutions (“the Center”), the health care research arm of Deloitte LLP. He brings a distinguished 30 year career in health services research in the private sector and academic medicine. He is a health economist and policy expert, and a regular contributor to CNN and Fox News health reform coverage. Dr. Keckley is considered one of the country’s leading experts on U.S. health reform.
    Prior to joining Deloitte, Dr. Keckley served in leadership roles at Vanderbilt Medical Center including international joint ventures, the Vanderbilt Center for Integrative Health, the health care MBA program launch, and as Executive Director of the Vanderbilt Center for Evidence-based Medicine (VCEBM). He has published several articles in peer reviewed journals and continues to serve in the Vanderbilt University School of Medicine as a Visiting Professor and the Owen Graduate School of Business at Vanderbilt as an Adjunct Professor.
    He completed his BA at Lipscomb University, MA and PhD degrees from Ohio State University, and a fellowship in economic policy at Oxford University.

    2:00 PM. Critical Sales and Distribution Considerations for the Buyer, Investor and Seller- Designing the Optimal Exit Strategy, Maximizing ROI and Minimizing Risk

    For many emerging healthcare and life science companies one of their largest financial investments and most important strategic decision is their approach to sales and distribution.  Determining the most optimal exit strategy is central to how emerging companies approach their sales and distribution models. In order to maximize valuation and minimize dilution at exit as well as minimize risk for the buyer, it is extremely important to choose the most optimal sales strategy to attract an acquiring company. If, for example, the acquiring company has its own national sales force, then building a full-scale sales and distribution model could be detrimental and may in fact negatively affect the sale. Instead finding ways to gain market traction on a small scale, with a proven scalable model, may be more efficient and less costly. This panel will discuss the critical considerations involved in building a sales model to facilitate a successful exit, and will offer a variety of perspectives for the life science buyer, seller, and investor. 

    Kevin Schimelfenig, Managing Partner, McGeever, LLC and SalesForce4Hire, LLC
    Michael Cain, Founder and Managing Partner, Guardant Partners LLC
    Kevin Nickels, Advisory Board, Tiberend Strategic Advisors, Inc.
    Full Bios

    Panels Friday June 24th

    8:30 AM. Healthcare Reform and Restructure: The Winners and the Losers

    Healthcare reform is changing the fundamentals and will affect the business models for a wide swath of the US healthcare sector. New institutions are being created such as Accountable Care Organizations and Health Insurance Exchanges which will dramatically impact health care delivery and payment models. Experts predict significant consolidation in a variety of sectors. This session on reform and restructuring will look at these fundamental changes and the potential impact for companies and investors. It will consider the likely areas of growth and decline and the considerable opportunities that may result for both entrepreneurs and private equity investors.

    Anne McGeorge, National Managing Partner, Health Care Practice, Grant Thorton, Panel Moderator
    Mark E. Toney, National Managing Principal, Grant Thorton
    Taylor Cole, Healthcare Services, Charterhouse Group
    Donald Dempsey, Senior Vice President, Marwood Group
    Seth Damergy, Vice President, Healthcare Investment Banking, Deutsche Bank
    Full Bios

    9:45 AM. Building a Healthcare Business in Europe

    Understanding Europe: A discussion of strategies for approaching Europe. Given the obstacles regulatory obstacles that exist in the United States, increasingly US companies are launching their businesses in Europe first. This session begins with an overview and understanding Europe. They will address the key issues in approaching Europe. With a variety of countries and languages, the differences in the regions, what issues do language differences pose? Is the European mindset different than in the US and how does this impact doing business or investing? Is it becoming more entrepreneurial? Can an outsider penetrate this market successfully? And what is an intelligent approach to accessing those who can help bring a product to market.

    Anthony Sun, Partner, Aisling Capital, Panel Moderator
    Daniel Bertholet, Investment Director, Endeavour Vision
    Thom Rasche, Partner, Earlybird Venture Capital
    Carla Kikken-Jussen, President, CEO and Founder, MediTech Strategic Consultants B.V
    Full Bios

    Note: It is the view of some expert investors that capital is raised at lower regulatory costs of launching Europeans expect that getting a business launched in Europe requires less capital than in the US. As such there a lower valuations but because there are lower capital needs founders end up with as much or more of the venture than if they were to build and launch in the US.

    11:00 AM. Accessing European Investment Capital for Healthcare and Life Science Companies

    Understanding European Investors: Increasingly European investors are becoming a significant resource for emerging companies. This panel will explore this opportunity and will address a number of questions. Does entering Europe provide access to European capital sources? Are European Investors different than US investors – more patient and longer term oriented? Are there differences in deal structure and negotiation than in the US? Does having a trans-Atlantic investor base add strategic value? What are the costs associated with trans-Atlantic ownership? Does a listing AIM or or other markets a good alternative for accessing capital via a public offering? What is the best strategy to access European investment capital?

    Pietro Strada, Managing Director, Centerboard Partners Limited
    John Milad, Investor, NBGI Ventures
    Full Bios
  • Conference Info:


    Date: June 26-27, 2013
    Location: The Metropolitan Club, New York City

    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    View the Schedule!

    View the Agenda!